Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Royal Bank of Canada — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while Royal Bank of Canada trades at $193.8 (market cap $268.76B). The key difference: Royal Bank of Canada is far larger — about 8.7× GE HealthCare Technologies Inc. Common Stock's market cap, and Royal Bank of Canada pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| GEHC | RY | |
|---|---|---|
Market Cap | $31.07B | $268.76B |
Volume | 3,443,020 | 1,509,016 |
Sector | Health | Financials |
52-Week High | $88.16 | $217.87 |
52-Week Low | $59.48 | $145.31 |
Enterprise Value | $39.53B | $738.98B |
Dividend Yield | 0.23% | 2.61% |
Typical Hold Time | — | 48 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Royal Bank of Canada (RY) trades at $193.82, up 0.55% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with net income margin improving to 32.01%. Analyst consensus leans neutral with 43% buy ratings while technical indicators show resistance near $194.
RY presents a mixed outlook with robust profitability and dividend stability offset by stretched valuations and bearish technicals. The bank's 18% ROE and U.S. expansion provide upside potential, though high P/E of 17.5 and negative cash flow trends warrant caution. Near-term performance hinges on Q3 earnings due October 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
